Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Improved migraine toolkit to save up to 16,500 emergency hospital admissions every year

An improved migraine care service as part of the NHS Long Term Plan is expected to save up to 16,500 emergency hospital admissions every year, NHS England said.

The NHS RightCare Headache and Migraine Toolkit will help local health groups to understand the scale of the migraine problem in their respective area and roll out tried and tested solutions which improve services for patients and free up money and staff time.


The toolkit is developed by clinical experts in the NHS and the Neurological Alliance.

Hugh McCaughey, NHS National Director for Improvement, said: “Headaches and migraines can place a heavy burden on sufferers, the NHS and the wider economy, but we know that there are local health services which are doing really well in meeting people’s needs early in the community, and therefore reducing the need for hospital care.”

“As they work with staff, patients and local partners to implement the NHS Long Term Plan, this initiative will provide all local NHS leaders with the information and proven ideas they need to deliver high-quality headache and migraine services to every communities.”

According to NHS Digital data, the number of hospital admissions in England for headaches and migraines has increased by 14 per cent over the last five years, from 95,548 emergency admissions in 2014-15 to 108,711 in 2018-19.

At the same time, around 2.5 million primary care appointments are linked to headaches and migraines, in which around 100,000 are referred to hospital for further assessment.

More For You

Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less
NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less